Alex Wang

Experience

• 

  Taiwan Air Force

  Jul 1998 - Apr 2000

  2nd Lieutenant, Supply and Account Officer

  • Ensured optimal inventory control of and budget for medical supply for entire command.• Supervised officers from 11 bases on the implementation of inventory control measures.

• 

  Eli Lilly and Company

  Apr 2000 - Jul 2004

  • Developed the market penetration strategy for neuroscience brand team contributing to an increase in market share from 10% to 13.7% in 2003. Established relationships with worldwide key opinion leaders from NIH, Mayo Clinic and Queen Square (UK), implementing a series of symposia on Parkinson’s Disease.• Received Achievement Award in 2002 and 2003 by contributing 43% of total annual sales growth. • Led sales training program for entire Taiwanese affiliate sales force focusing on the following courses: Performance Management, Health Care Transaction Model (Marketing Plan/ Strategy), Skills of Probing, Selling, and Negotiating, Handling Objection, and Presentation Skills. • Increased customer base of neurologists for the promotion of Anti-Parkinson’s Disease agent. • Established good rapport with healthcare professional team to influence prescribing behavior.

  • Sales Specialist

    Aug 2002 - Jul 2004

  • Sales Training Associate

    Jan 2002 - Aug 2002

  • Medical Representative

    Apr 2000 - Jan 2002
• 

  Orient Europharma Co., Ltd

  Sept 2004 - Aug 2005

  Product Manager/ Assistant Product Manager

  • Created the marketing strategy and revamped brand image and core messages for five cardiovascular products, exceeded annual sales targets, earning US$9.7 M, and increased record annual revenue growth by 53%. Managed annual budget of US$1.1 Million.

• 

  Ethicon, Johnson & Johnson

  Jun 2006 - Jan 2007

  New Business Development Associate (Co-op)

  • Provided detailed market analysis and competitive intelligence on new market opportunities to Worldwide NBD Director and Ethicon Products President on a periodic and project basis. • Member of global marketing team, providing recommendations to executive management to facilitate License & Acquisition decisions, resulting in one of the projects reaching definite acquisition agreement in 2008 with Mentor Corporation. Net transaction value is US$ 1.12 B.

• 

  Janssen, Johnson & Johnson

  Jul 2007 - Jul 2011

  • Developed pre-marketing strategies for Immunology (Simponi and Stelara) and HIV products (Prezista, Intelence), combined sales reaching US$ 50 M in 2017 in Taiwan market.• Led cross-functional team (Regulatory, Medical affairs, Health Economics, Logistics and Finance) to implement the launch readiness plan. Designed co-marketing structure with Mitsubishi-Tanabe Pharmaceutical. • Created product message “3, 3, 5, S” as a communication platform between sales team and physicians.• Developed and led SIMPONI promotional campaigns; achieving 1.4% market share in year 1. • Was granted Encore award for outstanding marketing initiatives and excellent trainings to the sales team. • Initiated marketing activities (5-Patient program, pain survey) for doctors to gain clinical experiences on the pain product. These programs established rapport between sales force and doctors, resulting in 409% growth rate in 2008 Q4 compared to 2008 Q1.

  • Senior Product Manager

    Feb 2010 - Jul 2011

  • Product Manager

    Feb 2009 - Feb 2010

  • Product Manager

    Jul 2007 - Feb 2009
• 

  ICARES Medicus, Inc.

  Aug 2011 - Apr 2012

  Sales & Marketing Director

  • Founding executive of the startup company, the first high-end intraocular lens (IOL) manufacturer in Taiwan• Led business development team and entered strategic partnership with Millennium Biomedical (USA) to penetrate local and global IOL market.• Developed global sales, marketing and regulatory strategies for intraocular lens (class III) and IOL delivery system (Class I or II).

• 

  Orient Europharma Co., Ltd

  Jul 2012 - Apr 2016

  • Turned around the business in 2014 and 2015 as profit-making unit.• Achieved 139% and 117% of sales target respectively for Neurology products Neupro and Vimpat in 2014 with growth rate of 65% and 198% (2014 vs 2013), attributed to right customer targeting and execution of marketing activities. • Successfully launched a breakthrough product in the treatment of Uterine Fibroid in OBGYN sector by accurate price-setting, target customer selection, branding and expediting enlistment progress.• Oversee and direct various functions of sales, marketing, regulatory, finance, logistics, HR/Admin staff to ensure daily business operations. Show less

  • General Manager & Head of Pharma Business

    Jun 2014 - Apr 2016

  • CEO Office Strategic Alliance Manager

    Jul 2012 - Jun 2014
• 

  波士頓科技

  Apr 2016 - May 2017

  BU head

  Lead team of 8, including 1 Marketing Manager, 6 Territory/Product/Distributor Manager and 1 sales/marketing administrator; 25 sales staff from distributors’ side. Have full responsibility of the P&L. In 2016, 112% achievement rate over the target with 23% growth rate. As of April 2017, 125% achievement rate and 39% growth rate. Continuous growth came from a game-changer mindset when launching new products and distributor optimization strategy

• 

  賽諾菲

  Dec 2017 - Apr 2018

  Head of Business Unit

  Lead the new product launch strategy to ensure commercial launch excellence across two markets (TW/HK); cross-functional collaboration with market access, medical, and regional stakeholders.

• 

  Roche

  Jul 2018 - Feb 2020

  Consultant
• 

  ALMAR Biotech

  Jan 2020 - now

  General Manager